| Drug name | Alternative names | Category |
|---|---|---|
| Pancreatic tumor cell vaccine | Vaccine | |
| CEA (CAP1-6D) peptide | Vaccine | |
| Antibody ganitumab (AMG-479) | Monoclonal antibody inhibitor of IGF-IR | |
| Dalotuzumab | MK-0646 | Humanized monoclonal antibody |
| Avicine | Vaccine | |
| GVAX vaccine | CG 8123 | Vaccine |
| RAS 5-17 peptide vaccine | Vaccine | |
| Oncophage | Heat shock protein-peptide complex (HSPPC-96) | Vaccine |
| RC-3095 | Bombesin/gastrin releasing peptide antagonist | |
| Cetuximab | Erbitux, C-225/IMC-C225 | Monoclonal antibody, anti-EGFR antibody |
| TNFerade | Gene therapy | |
| Gastrimmune | Vaccine | |
| P53 and RAS vaccine | Vaccine | |
| CEA-Vac | Vaccine | |
| BrevaRex | Passive monoclonal antibody | |
| O-Vax | Vaccine | |
| Recombinant soluable PSMA vaccine | Vaccine | |
| Telomerase cancer vaccine | Vaccine | |
| Anti-gastrin therapeutic vaccine | Vaccine | |
| Virulizin | Macrophage activator | |
| Vaccinia-MUC-1 vaccine | Vaccine | |
| PanVac | Vaccine | |
| P16 program | Gene therapy | |
| CEA-cide | Anti-CEA monoclonal antibody | |
| Peripheral blood lymphocytes transduced with a gene encoded chimeric T-cell receptor | Gene therapy | |
| Trastuzumab | Anti-erbB2 monoclonal antibody, Anti-HER2/c-erbB2 monoclonal antibody | Targeted therapy—epidermal growth factor receptor |
| Keytruda | MK-3475, SCH-900475, Lambrolizumab, Pembrolizumab | Monoclonal antibody |
CAP1-6D, carcinoembryonic antigen peptide 1-6D; EGFR, epidermal growth factor receptor; erbB, erythroblastic oncogene B; GVAX, GM-CSF gene transduced autologous pancreatic cancer vaccine; IGF-IR, insulin-like growth factor receptor; MUC-1, mucin 1; PSMA, prostate specific cancer antigen human recombinant; TNF, tumor necrosis factor.